Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04321954 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
A Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT04321954 is a Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 30 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04321954, a Phase 2 study of Advanced Cancer and Differentiated Thyroid Cancer, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Conditions Studied
Interventions
- DRUG LENVATINIB
Study Locations (3)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2026-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04321954
The ClinicalTrials.gov registry entry for NCT04321954 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which LENVATINIB is the first listed.
NCT04321954 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT04321954 about?
NCT04321954 is a clinical study titled "Lenvatinib in Locally Advanced Invasive Thyroid Cancer". This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
What is the current status of trial NCT04321954?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-03-09. Estimated completion is 2026-05-27.
What conditions does trial NCT04321954 study?
This clinical trial studies the following conditions: Advanced Cancer, Differentiated Thyroid Cancer.
What interventions are being tested in trial NCT04321954?
The interventions under investigation include: LENVATINIB (DRUG).
Who is sponsoring clinical trial NCT04321954?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04321954 being conducted?
This trial has 3 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Psilocybin Therapy in Advanced Cancer
RECRUITING · Phase 2
-
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.